Oncolytics Biotech, Inc.

Oncolytics Biotech Inc. is a development-stage biotechnology company focused on the creation of a novel class of cancer therapeutics. Its primary objective is to develop pelareorep, an intravenously delivered immuno-oncolytic virus designed to target and destroy cancer cells while leaving normal cells intact. This unique therapeutic approach aims to harness the body's immune system to combat cancer more effectively, potentially offering new hope for patients with various malignancies. Oncolytics Biotech Inc. plays a significant role in the oncology sector, particularly in the development of treatments for cancers that do not respond well to traditional therapies. With ongoing clinical trials and research collaborations, Oncolytics Biotech Inc. is positioned within the biotechnology industry as a pioneer of viral-based cancer treatment innovations, continually advancing its methodologies to improve patient outcomes and extend the therapeutic possibilities of immune-oncology.